This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Untold Story Of An Unnecessary National Health Crisis

PRAIRIEVILLE, La., Dec. 6, 2012 /PRNewswire/ -- A Louisiana man is telling the story of a largely unknown American health crisis involving the nation's blood supply, that claimed thousands of lives due to national irresponsibility and lack of proactive oversight.

Gary William Cross recalls his pivotal role in what was called the nation's "hemophilia HIV pandemic" in his new memoir, Vial 023: A Father's Pursuit of Justice. The book tells how Cross' hemophiliac son, Brad, died in April 1993 after becoming infected with HIV through contaminated blood supplies used for his clotting factor treatment. He was 17.

As thousands of other hemophiliacs were infected and subsequently died, Cross and his wife, Karen, became leading figures in the campaign to find out how blood from high-risk donors came to be used in manufacturing the medication that was supposed to protect its users.

Over the course of more than a decade, Cross played a key role in legal discovery and proceedings to determine what went wrong to make sure that it could never happen again. His efforts culminated in a remarkable, behind-closed-doors meeting between some of the families of those who died and representatives from the pharmaceutical companies responsible. The meeting resulted in an unprecedented legal settlement that ended years of courtroom fighting.

The Crosses and their daughter Jennifer were featured in the 1996 award-winning 60 Minutes program, "Bad Blood," telling of the HIV crisis within the hemophilia community. But apart from that documentary—made before the legal settlements and governmental oversight changes that were finally realized—the tragic events have largely gone untold.

"I felt like the story was fading away, and that it was important to record some of the history of what happened so that no one ever has to face anything like this again," said Cross. "I hope my book will be a helpful reminder, and encourage people to continue to ensure that we have a clean blood supply."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs